Table 2.
Summary of the clinical parameters of patients with rheumatoid arthritis
| Responders | Non- or moderate responders | Responders | Non- or moderate responders | ||
|---|---|---|---|---|---|
| Test cohort | Validation cohort | Difference | |||
| At baseline | 6 | 13 | 4 | 11 | |
| Gender (male/female) | 1/5 | 2/11 | 0/4 | 3/8 | |
| Age (years) | 44.3±9.3 | 47±10.7 | 54±17 | 56.2±6.8 | Non-significant |
| DAS28 | 5.6±0.3 | 5.2±0.7 | 5.2±0.06 | 5.4±0.5 | Non-significant |
| HAQ | 1.2±0.7 | 2±0.6 | 1.5±1.1 | 1.9±0.7 | Non-significant |
| CRP (mg/ml) | 16.8±18.3 | 28.3±23.8 | 18.9±18.3 | 9.5±10.3 | Non-significant |
| DMARDs | 2.8±0.9 | 2.6±0.7 | 3±0.8 | 2.7±1.4 | Non-significant |
CRP, C-reactive protein;DAS28, Disease Activity Score; HAQ, Health Assessment Questionnaire; DMARD, disease-modifying anti-rheumatic drug (methotrexate). Data are shown as mean±SD.